Table 2 Bronchoscopy characteristics
| Â | Â | Sub-cohorts used for: | ||
|---|---|---|---|---|
Main cohort N = 126* | CCSP & SP-D N = 20* | Inflammatory proteins N = 15* | Cell count N = 6* | |
Median time from transplant to bronchoscopy, days, Median (IQR) | 279 (99.5–553) | 189 (95–316) | 196 (67.5–285) | 189 (93.8–280.5) |
Indication for bronchoscopy | ||||
 Surveillance | 104 (82.5%) | 15 (75%) | 11 (73.3%) | 5 (83.3%) |
 Diagnostic | 22 (17.5%) | 5 (25%) | 4 (26.7%) | 1 (16.7%) |
BAL localization | ||||
 RUL | 5 (4%) | 2 (10%) | 1 (6.7%) | 0 |
 RML | 103 (81.7%) | 15 (75%) | 11 (73.3%) | 4 (66.7%) |
 RLL | 4 (3.2%) | 1 (5%) | 1 (6.7%) | 1 (16.7%) |
 LUL | 8 (6.3%) | 2 (10%) | 1 (6.7%) | 1 (16.7%) |
 LLL | 2 (1.6%) | 0 | 1 (6.7%) | 0 |
 Missing records | 4 (3.2%) | 0 | 0 | 0 |
FEV1 at the time of bronchoscopy, L (Median, IQR) | 2.2 (1.6–2.8) | 2 (1.7–3.1) | 2 (1.8–2.25) | 2 (1.8–2.4) |
Presence of clinically-relevant pathogen, number | 29 (23%) | 6 (30%) | 2 (13.3%) | 1 (16.7%) |
AR grade | ||||
 AX | 15 (11.9%) | 4 (20%) | 1 (6.7%) | 2 (33.3%) |
 A0 | 76 (60.3%) | 13 (65%) | 9 (60%) | 4 (66.7%) |
 A1 | 22 (17.5%) | 3 (15%) | 4 (26.7%) | 0 |
  ≥ A2 | 0 | 0 | 0 | 0 |
 Biopsy not done | 13 (10.3%) | 0 | 1 (6.7%) | 0 |